Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasm Metastasis 2Ovarian Neoplasms 1Malignant Female Reproductive System Neoplasm 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Bevacizumab 12olaparib 10Paclitaxel 10Carboplatin 10liposomal doxorubicin 7Specimen Handling 7Magnetic Resonance Spectroscopy 6mirvetuximab soravtansine 4Topotecan 4Taxes 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Biopsy 4pembrolizumab 3cediranib 3Oxaliplatin 2Doxorubicin 21-dodecylpyridoxal 2tremelimumab 1trastuzumab deruxtecan 1sotorasib 1sarilumab 1palbociclib 1niraparib 1nilotinib 1neratinib 1irinotecan sucrosofate 1ipatasertib 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × neratinib × 30 days × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡